Anhedonia and major depression: The role of agomelatine

European Neuropsychopharmacology

Volumn 22, Issue SUPPL3, 2012, Pages

  Di Giannantonio, Massimo ^a   Martinotti, Giovanni ^a  

^a C/o Mental Health Department ^*  (Italy)

Author keywords

Agomelatine; Anhedonia; Depression; Pleasure; SHAPS

Indexed keywords

AGOMELATINE; SERTRALINE; VENLAFAXINE;

ANHEDONIA; ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SINGLE DRUG DOSE; SNAITH HAMILTON PLEASURE SCALE; TREATMENT DURATION;

ACETAMIDES; ANHEDONIA; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 84865840272     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.07.004     Document Type: Article

References (61)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Press, Washington, DC, (Text Revision (DSM-IV-TR)). fourth ed.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 1989, 7:49-58.
3. Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr. Scand. 2002, 106:252-264.
4. Berlin I., Givry-Steiner L., Lecrubier Y., Puech A.J. Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. Eur. Psychiatry 1998, 13:303-309.
5. Bleuler E. Dementia Praecox oder Gruppe der Schizophrenien/Dementia Praecox or the Group of Schizophrenias 1911, International Universities Press, New York.
6. Boyer P., Tassin J.P., Falissart B., Troy S. Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression. J. Clin. Pharm. Ther. 2000, 25:363-371.
7. Chapman L.J., Chapman J.P., Raulin M.L. Scales for physical and social anhedonia. J. Abnorm. Psychol. 1976, 85:374-382.
8. Davis C., Woodside D.B. Sensitivity to the rewarding effects of food and exercise in the eating disorders. Compr. Psychiatry 2002, 43:189-194.
9. De Berardis D., Conti C.M., Serroni N., Moschetta F.S., Olivieri L., Carano A., Salerno R.M., Cavuto M., Farina B., Alessandrini M., Janiri L., Pozzi G., Di Giannantonio M. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int. J. Immunopathol. Pharmacol. 2010, 23(2):417-422.
10. De Bodinat C., Guardiola-Lemaitre B., Mocaer E., Renard P., Munoz C., Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 2010, 9(8):628-642.
11. Di Giannantonio M., Di Iorio G., Guglielmo R., De Berardis D., Conti C.M., Acciavatti T., Cornelio M., Martinotti G. Major depressive disorder, anhedonia and agomelatine: an open-label study. J. Biol. Regul. Homeost. Agents 2011, 25(1):109-114.
12. Dryman A., Eaton W.W. Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr. Scand. 1991, 84(1):1-5.
13. Farina B., Della Marca G., Mennuni G., et al. The effects of reboxetine on human sleep architecture in depression: preliminary results. J. Affect. Disord. 2002, 71:273-275.
14. Fawcett J., Clark D.C., Scheftner W.A., Gibbons R.D. Assessing anhedonia in psychiatric patients. Arch. Gen. Psychiatry 1983, 40:79-84.
15. Fawcett J. The morbidity and mortality of clinical depression. Special Issue: affective disorders: current and future perspectives. Int. Clin. Psychopharmacol. 1993, 8:217-220.
16. Franken I.H.A., Rassin E., Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J. Affect. Disord. 2007, 99:83-89.
17. Franken I.H.A., Van Strien J.W., Nijs I. Effect of hedonic tone on event-related potential measures of cognitive processing. Psychiatry Res. 2006, 142:233-239.
18. Franken I.H.A., Zijlstra C., Muris P. Are nonpharmacological induced rewards related to anhedonia? A study among skydivers. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:297-300.
19. Gard D.E., Gard M.G., Kring A.M., John O.P. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J. Res. Pers. 2006, 40:1086-1102.
20. Gilbert P., Allan S., Brough S., Melley S., Miles J.N.V. Relationship of anhedonia and anxiety to social rank, defeat, and entrapment. J. Affect. Disord. 2002, 71:141-151.
21. Goodwin G.M., Emsley R., Rembry S., Rouillon F. Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009, 70(8):1128-1137. (Epub 2009).
22. Hasler B.P., John Allen J.B., David Sbarra A., Richard Bootzin R., Rebecca Bernert A. Phase relationships between core body temperature, melatonin, and sleep are associated with depression severity: further evidence for circadian misalignment in non-seasonal depression. Psychiatry Res. 2010, 178:205-207.
23. Hickie IB., Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011, 378(9791):621-631.
24. Isella V., Iurlaro S., Piolti R., Ferrarese C., Frattola L., Appollonio I., Melzi P., Grimaldi M. Physical anhedonia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74:1308-1311.
25. Janiri L., Martinotti G., Dario T., Reina D., Paparello F., Pozzi G., Addolorato G., Di Giannantonio M., De Risio S. Anhedonia andsubstance-related symptoms in detoxified substance dependent subjects: a correlation study. Neuropsychobiology 2005, 52:37-44.
26. Jaspers K. Allgemeine Psychopathologie. Ein Leitfaden für Studierende, Ärzte und Psychologen. Auflage 1913, Springer, Berlin.
27. Kasper S., Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J. Biol. Psychiatry 2009, 10(2):117-126.
28. Kasper S., Hajak G., Wulff K., Hoogendijk W.J., Montejo A.L., Smeraldi E., Rybakowski J.K., Quera-Salva M.A., Wirz-Justice A.M., Picarel-Blanchot F., Baylé F.J. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J. Clin. Psychiatry 2010, 71(2):109-120.
29. Keedwell P.A., Andrew C., Williams S.C., Brammer M.J., Phillips M.L. The neural correlates of anhedonia in major depressive disorder. Biol. Psychiatry 2005, 58:843-853.
30. Kennedy SH., Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS. Drugs. 2010, 24(6):479-499.
31. Kennedy SH., Rizvi S., Fulton K., Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol. 2008, 28(3):329-333.
32. Klein D. Depression and anhedonia. Anhedonia and Affect Deficit States 1984, 1-14. PMA Publishing, New York. C. Clark, J. Fawcett (Eds.).
33. Keedwell P.A., Andrew C., Williams S.C., Brammer M.J., Phillips M.L. The neural correlates of anhedonia in major depressive disorder. Biol. Psychiatry 2005, 58(11):843-853.
34. Kraepelin E. Dementia Praecox and Paraphrenia 1919, Huntington, New York.
35. Lemoine P., Guilleminault C., Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry 2007, 68(11):1723-1732.
36. Leventhal A.M., Chasson G.S., Tapia E., Miller E.K., Pettit J.W. Measuring hedonic capacity in depression: a psychometric analysis of three anhedonia scales. J. Clin. Psychol. 2006, 62(12):1545-1558.
37. Loas G., Pierson A. Anhedonia in psychiatry: a review. Ann. Med. Psychol. (Paris) 1989, 147:705-717.
38. Loas G. Vulnerability to depression: a model centered on anhedonia. J. Affect. Disord. 1996, 41:39-53.
39. Loo H., Hale A., D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 2002, 17:239-247.
40. Martinotti G., Carli V., Tedeschi D., Di Giannantonio M., Roy A., Janiri L., Sarchiapone M. Mono- and polysubstance dependent subjects differ on social factors, childhood trauma, personality, suicidal behaviour, and comorbid Axis I diagnoses. Addict. Behav. 2009, 34(9):790-793.
41. Martinotti G., Sepede G., Gambi F., Di Iorio G., De Berardis D., Di Nicola M., Onofrj M., Janiri L., Di Giannantonio M. Agomelatine versus Venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J. Clin. Psychopharmacol. 2012, 32(4):487-491.
42. Mason O., Startup M., Halpin S., Schall U., Conrad A., Carr V. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr Res. 2004, 71(2-3):227-237.
43. Montgomery SA., Kennedy SH., Burrows GD., Lejoyeux M., Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol 2004, 19(5):271-280.
44. Monteleone P., Martiadis V., Maj M. Circadian rhythms and treatment implications in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(7):1569-1574. (Aug 15).
45. Mottola C.A. Measurement strategies: the visual analogue scale. Decubitus 1993, 6(5):56-58.
46. Myerson A. Anhedonia. Am. J. Psychiatry 1923, 2:87-103.
47. Oei T.I., Verhoeven W.M., Westenberg H.G., Zwart F.M., van Ree J.M. Anhedonia, suicide ideation and dexamethasone nonsuppression in depressed patients. J. Psychiatr. Res. 1990, 24:25-35.
48. Olie J.P., Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol. 2007, 10(5):661-673.
49. Racagni G., Riva MA., Molteni R., Musazzi L., Calabrese F., Popoli M., et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J. Biol. Psychiatry. 2011, 12(8):574-587.
50. Ribot T. La Psychologie Des Sentiments 1896, Felix Alcan, Paris.
51. Schrader G.D. Does anhedonia correlate with depression severity in chronic depression?. Compr. Psychiatry 1997, 38:260-263.
52. Silverstone P.H. Is anhedonia a good measure of depression?. Acta Psychiatr. Scand. 1991, 83:249-250.
53. Snaith P. Anhedonia: exclusion from the pleasure dome. BMJ 1992, 305(6846):134.
54. Snaith R.P., Hamilton M., Morley S., Humayan A., Hargreaves D., Trigwell P. A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. Br. J. Psychiatry 1995, 167:99-103.
55. Snaith R.P. Anhedonia: a neglected symptom of psychopathology. Psychol. Med. 1993, 23:957-966.
56. Spijker J., Bijl R.V., de Graaf R., Nolen W.A. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr. Scand. 2001, 103(2):122-130.
57. Stahl S.M., Fava M., Trivedi M.H., Caputo A., Shah A., Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatry 2010, 71(5):616-626.
58. Stahl S.M., Entsuah R., Rudolph R.L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry 2002, 52(12):1166-1174. (Dec 15).
59. Tardito, D., Molteni, R., Popoli, M., Racagni, G., Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur. Neuropsychopharmacol. , in press. http://dx.doi.org/10.1016/j.euroneuro.2012.06.016.
60. Taylor D.J., Walters H.M., Vittengl J.R., et al. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?. J. Affect. Disord. 2010, 123(1-3):181-187.
61. Zajecka J., Schatzberg A., Stahl S., Shah A., Caputo A., Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2010, 30(2):135-144. (2010).